Predictive Oncology Featured in Broadcast Evaluating Targeted Cancer Therapies, Higher Survival Rates
November 07 2019 - 8:30AM
via NetworkNewsAudio –
Predictive Oncology
(NASDAQ: POAI) announces the availability of a broadcast
titled, “New Hope in the Battle Against Ovarian Cancer.”
To hear the NetworkNewsWire Audio version, visit:
http://nnw.fm/L4Kxb
To read the full editorial, visit: http://nnw.fm/Px2x7
There’s a paradigm shift occurring in
cancer therapeutics, and ovarian cancer patients look to be the
beneficiaries. Treatment protocols for ovarian cancer have
historically consisted of a combination of surgery and
chemotherapy. However, the scientific community has come to the
realization that, given the vagaries and complexities of a
patient’s cancer, targeted therapeutics are imperative to increase
survival rates. To administer exactly the right drug or drug
combinations that give a patient the best chance of survival
requires comprehensive molecular information.
That’s why the work of
Predictive Oncology (NASDAQ: POAI) is so
important. Predictive Oncology’s subsidiary, Helomics, currently
has about 150,000 cases on its molecular information platform,
38,000 of which are specific to ovarian cancer. This unique and
valuable scientific asset places Predictive Oncology among the
leaders in providing the critical molecular information needed for
more effective patient treatments and new drug discovery.
About Predictive Oncology Inc.
Predictive Oncology is an AI-driven company focused on applying
artificial intelligence to personalized medicine and drug
discovery. The company applies smart tumor profiling and its AI
platform to extensive genomic and biomarker patient data sets to
predict clinical outcomes and, most importantly, improve patient
outcomes for cancer patients of today and tomorrow. Predictive
Oncology currently has approximately 150,000 clinically validated
cases on its molecular information platform, with more than 38,000
specific to ovarian cancer. The company’s data is highly
differentiated, having both drug-response data and access to
historical outcome data from patients. Predictive Oncology intends
to generate additional sequence data from these tumor samples to
deliver on the clear unmet market need across the pharmaceutical
industry for a multi-omic approach to new drug development. For
more information, visit the company’s website
at www.Predictive-Oncology.com.
About NetworkNewsAudio
NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution, allows
you to sit back and listen to market updates, CEO interviews and a
Company AudioPressRelease (APR). These audio clips provide
snapshots of position, opportunity and
momentum. NetworkNewsAudio (NNA) can assist your company
by cutting through the overload of information in today's market,
NNA brings its clients unparalleled visibility, recognition and
brand awareness. NetworkNewsWire (NNW) is where news,
content and information converge. NetworkNewsWire
(NNW) is a comprehensive provider of news aggregation and
syndication, enhanced press release services and a full array of
social communication solutions. As a multifaceted financial news
and distribution company with an extensive team of journalists and
writers, NNW has the unparalleled ability to reach a wide audience
of investors, consumers, journalists and the general public with an
ever-growing distribution network of more than 5,000 key
syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the
NetworkNewsWire website applicable to all content provided by NNW,
wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications:
NetworkWire (NW) New York, New York www.NetworkNewsWire.com
212.418.1217 Office Editor@NetworkWire.com
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024